| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
|
Nakamura, Y.
|
|
|
6 |
6 |
p.
|
article
|
| 2 |
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
|
Cerbone, L.
|
|
|
6 |
6 |
p.
|
article
|
| 3 |
A user-friendly objective prediction model in predicting colorectal cancer based on 234 044 Asian adults in a prospective cohort
|
Chen, C.H.
|
|
|
6 |
6 |
p.
|
article
|
| 4 |
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
|
D'Angelo, S.P.
|
|
|
6 |
6 |
p.
|
article
|
| 5 |
Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
|
Zhou, T.
|
|
|
6 |
6 |
p.
|
article
|
| 6 |
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
|
Coleman, N.
|
|
|
6 |
6 |
p.
|
article
|
| 7 |
Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer
|
Gou, Q.
|
|
|
6 |
6 |
p.
|
article
|
| 8 |
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
|
Rossini, D.
|
|
|
6 |
6 |
p.
|
article
|
| 9 |
Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’
|
Jain, P.
|
|
|
6 |
6 |
p.
|
article
|
| 10 |
Corrigendum to ‘Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review’
|
Garutti, M.
|
|
|
6 |
6 |
p.
|
article
|
| 11 |
Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’
|
Reck, M.
|
|
|
6 |
6 |
p.
|
article
|
| 12 |
Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation
|
Mulder, E.E.A.P.
|
|
|
6 |
6 |
p.
|
article
|
| 13 |
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey
|
Cufer, T.
|
|
|
6 |
6 |
p.
|
article
|
| 14 |
Distribution of the workforce involved in cancer care: a systematic review of the literature ☆
|
Trapani, D.
|
|
|
6 |
6 |
p.
|
article
|
| 15 |
Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020
|
Maliepaard, M.
|
|
|
6 |
6 |
p.
|
article
|
| 16 |
Editorial Board
|
|
|
|
6 |
6 |
p.
|
article
|
| 17 |
Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database
|
Bassompierre, A.
|
|
|
6 |
6 |
p.
|
article
|
| 18 |
Erratum to ‘How we treat medulloblastoma in adults’
|
Franceschi, E.
|
|
|
6 |
6 |
p.
|
article
|
| 19 |
Erratum to ‘How we treat primary central nervous system lymphoma’
|
Calimeri, T.
|
|
|
6 |
6 |
p.
|
article
|
| 20 |
Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
|
Berghoff, A.S.
|
|
|
6 |
6 |
p.
|
article
|
| 21 |
How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
|
Jordan, B.
|
|
|
6 |
6 |
p.
|
article
|
| 22 |
In the literature: October 2021
|
Gambardella, V.
|
|
|
6 |
6 |
p.
|
article
|
| 23 |
Letter re: ‘Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications’
|
Sullivan, W.G.
|
|
|
6 |
6 |
p.
|
article
|
| 24 |
Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study
|
Houvenaeghel, G.
|
|
|
6 |
6 |
p.
|
article
|
| 25 |
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
|
Tabernero, J.
|
|
|
6 |
6 |
p.
|
article
|
| 26 |
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
|
Rimini, M.
|
|
|
6 |
6 |
p.
|
article
|
| 27 |
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
|
Keam, B.
|
|
|
6 |
6 |
p.
|
article
|
| 28 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
|
Kanesvaran, R.
|
|
|
6 |
6 |
p.
|
article
|
| 29 |
Please mind the gap—about equity and access to care in oncology
|
Barcellini, A.
|
|
|
6 |
6 |
p.
|
article
|
| 30 |
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
|
Omar, N.E.
|
|
|
6 |
6 |
p.
|
article
|
| 31 |
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program ☆
|
Müller, V.
|
|
|
6 |
6 |
p.
|
article
|
| 32 |
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
|
Heilig, C.E.
|
|
|
6 |
6 |
p.
|
article
|
| 33 |
Response to comment on “Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications”
|
Krebs, M.G.
|
|
|
6 |
6 |
p.
|
article
|
| 34 |
Role and responsibility of oncologists in assisted suicide. Practice and views among members of the German Society of Haematology and Medical Oncology
|
Schildmann, J.
|
|
|
6 |
6 |
p.
|
article
|
| 35 |
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer
|
Condorelli, M.
|
|
|
6 |
6 |
p.
|
article
|
| 36 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial
|
Assenat, E.
|
|
|
6 |
6 |
p.
|
article
|
| 37 |
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment
|
Grinshpun, A.
|
|
|
6 |
6 |
p.
|
article
|
| 38 |
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
|
Munzone, E.
|
|
|
6 |
6 |
p.
|
article
|
| 39 |
Table of Contents
|
|
|
|
6 |
6 |
p.
|
article
|
| 40 |
The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis
|
Paakkola, N.-M.
|
|
|
6 |
6 |
p.
|
article
|
| 41 |
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
|
Di Noia, V.
|
|
|
6 |
6 |
p.
|
article
|
| 42 |
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
|
Franken, M.G.
|
|
|
6 |
6 |
p.
|
article
|
| 43 |
Vaccine third dose and cancer patients: necessity or luxury?
|
Pappas, G.
|
|
|
6 |
6 |
p.
|
article
|
| 44 |
Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study
|
Gray, E.
|
|
|
6 |
6 |
p.
|
article
|
Journal description